Several studies (5,17–19) have demonstrated that the expression of SPRY2 was downregulated or inhibited in prostate cancer, breast cancer and malignant glioma, leading to the deregulation and overactivation of MAPK/ERK signaling in tumor cells. This evidence concerns the gene SPRY2 and prostate carcinoma.